

Prophylactic transcatheter arterial embolization reduces rebleeding in non-variceal upper gastrointestinal bleeding: A meta-analysis

Eszter Boros, Zoltán Sipos, Péter Hegyi, Brigitta Teutsch, Levente Frim, Szilárd Váncsa, Szabolcs Kiss, Fanni Dembrovsky, Eduard Oštarijaš, Andrew Shawyer, Bálint Eröss

ORCID number: Eszter Boros 0000-0002-7831-163X; Zoltán Sipos 0000-0001-7845-8116; Péter Hegyi 0000-0003-0399-7259; Brigitta Teutsch 0000-0002-9530-7886; Levente Frim 0000-0003-0097-6663; Szilárd Váncsa 0000-0002-9347-8163; Szabolcs Kiss 0000-0001-5032-866X; Fanni Dembrovsky 0000-0001-6953-3591; Eduard Oštarijaš 0000-0001-9999-9886; Andrew Shawyer 0000-0003-1700-3307; Bálint Eröss 0000-0003-3658-8427.

Author contributions: Boros E, Sipos Z, Hegyi P, Teutsch B, Frim L, Váncsa S, Kiss S, Dembrovsky F, Oštarijaš E, Shawyer A, and Eröss B provided the conceptualization; Boros E is the project administration; Boros E and Sipos Z formally analyze the original draft; Boros E and Teutsch B did the systematic search and selection, and wrote the original draft; Sipos Z made the visualisation, and wrote the original draft; Hegyi P contributed to the funding acquisition; Hegyi P, Frim L, Váncsa S, Kiss S, Dembrovsky F, Oštarijaš E, and Shawyer A wrote, reviewed and edited the manuscript; Frim L contributed to the data curation, quality and risk assessment; Váncsa S and Kiss S provided the methodology, and made the data curation; Dembrovsky F provided the methodology, and made the

Eszter Boros, Zoltán Sipos, Péter Hegyi, Brigitta Teutsch, Levente Frim, Szilárd Váncsa, Szabolcs Kiss, Fanni Dembrovsky, Eduard Oštarijaš, Bálint Eröss, Institute for Translational Medicine, University of Pecs, Medical School, Pécs 7624, Hungary

Eszter Boros, First Department of Internal Medicine, St. George University Teaching Hospital of County Fejér, Székesfehérvár 8000, Hungary

Péter Hegyi, Szentágotthai Research Center, University of Pecs, Pécs 7624, Hungary

Szabolcs Kiss, Doctoral School of Clinical Medicine, University of Szeged, Szeged 6720, Hungary

Andrew Shawyer, Department of Interventional Radiology, University Hospitals Dorset NHS Foundation Trust, Bournemouth BH7 7DW, United Kingdom

Corresponding author: Bálint Eröss, MD, PhD, Assistant Professor, Doctor, Institute for Translational Medicine, University of Pecs, Medical School, 12 Szigeti Street, Pécs 7624, Hungary. eross.balint@pte.hu

Abstract

BACKGROUND

Despite the improvement in the endoscopic hemostasis of non-variceal upper gastrointestinal bleeding (NVUGIB), rebleeding remains a major concern.

AIM

To assess the role of prophylactic transcatheter arterial embolization (PTAE) added to successful hemostatic treatment among NVUGIB patients.

METHODS

We searched three databases from inception through October 19th, 2020. Randomized controlled trials (RCTs) and observational cohort studies were eligible. Studies compared patients with NVUGIB receiving PTAE to those who did not get PTAE. Investigated outcomes were rebleeding, mortality, reintervention, need for surgery and transfusion, length of hospital (LOH), and intensive care unit (ICU) stay. In the quantitative synthesis, odds ratios (ORs) and weighted mean differences (WMDs) were calculated with the random-effects model and interpreted with 95% confidence intervals (CIs).

quality and risk assessment; Oštarijaš E did the visualization; Eröss B did the conceptualization, supervision, and wrote the original draft; All authors certify that they have participated sufficiently in the work to take public responsibility for the content, including participation in the concept, design, analysis, writing, or revision of the manuscript.

Supported by Economic Development and Innovation Operative Programme Grant, No. GINOP 2.3.2-15-2016-00048 and No. GINOP-2.3.4-15-2020-00010; and Human Resources Development Operational Programme Grant, No. EFOP-3.6.2-16-2017-00006 and No. EFOP-3.6.1-16-2016-00004.

Conflict-of-interest statement: No conflict of interest to declare.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2020 Checklist, and was prepared and revised according to the PRISMA 2020 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Country/Territory of origin: Hungary

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): B, B, B

RESULTS

We included a total of 3 RCTs and 9 observational studies with a total of 1329 patients, with 486 in the intervention group. PTAE was associated with lower odds of rebleeding (OR = 0.48, 95%CI: 0.29–0.78). There was no difference in the 30-d mortality rates (OR = 0.82, 95%CI: 0.39–1.72) between the PTAE and control groups. Patients who underwent PTAE treatment had a lower chance for reintervention (OR = 0.48, 95%CI: 0.31–0.76) or rescue surgery (OR = 0.35, 95%CI: 0.14–0.92). The LOH and ICU stay was shorter in the PTAE group, but the difference was non-significant [WMD = -3.77, 95%CI: (-8.00)–0.45; WMD = -1.33, 95%CI: (-2.84)–0.18, respectively].

CONCLUSION

PTAE is associated with lower odds of rebleeding and any reintervention in NVUGIB. However, further RCTs are needed to have a higher level of evidence.

Key Words: Prophylactic transcatheter arterial embolization; Non-variceal upper gastrointestinal bleeding; Rebleeding; Reintervention; Meta-analysis; Review

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Rebleeding remains a significant concern in patients with non-variceal upper gastrointestinal bleeding (NVUGIB), despite the improvements in endoscopic and pharmacologic treatments. Our systematic review and meta-analysis indicate that prophylactic transcatheter arterial embolization (PTAE) compared to standard of care is accompanied by lower odds of rebleeding, need for rescue surgery, and reinterventions NVUGIB. However, we could not justify a beneficial effect of PTAE on mortality rates compared with the standard of care. In line with our results, we suggest using PTAE in selected cases, where risk stratification predicts high rebleeding risk or the anatomical situation makes the secure and permanent endoscopic hemostasis impossible.

Citation: Boros E, Sipos Z, Hegyi P, Teutsch B, Frim L, Vánca S, Kiss S, Dembrowszky F, Oštarijaš E, Shawyer A, Eröss B. Prophylactic transcatheter arterial embolization reduces rebleeding in non-variceal upper gastrointestinal bleeding: A meta-analysis. *World J Gastroenterol* 2021; 27(40): 6985-6999

URL: <https://www.wjgnet.com/1007-9327/full/v27/i40/6985.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v27.i40.6985>

INTRODUCTION

Acute upper gastrointestinal bleeding (UGIB) remains a common medical emergency with an incidence of 47-90/100000[1-3]. The age-standardized incidence of ulcer bleeding decreased by 41.6% between 1983 and 2004 in a prospective observational study; notable the decrease occurred only in people younger than 70 years of age[1]. Mortality in UGIB ranges between 1.1%–11% [4], although it has significantly decreased due to improvements and innovation in both endoscopic and pharmacologic treatments[1,4]. The UGIB population characteristics have changed considerably, the mean age of the patients has increased, the prevalence of co-morbidities is higher than before, and the use of nonsteroidal anti-inflammatory, antiplatelet and anticoagulant drugs is more widespread[1,5,6].

Rebleeding is a significant concern in patients with UGIB, occurring in 7%–16% of cases despite endoscopic therapy[6]. As published in a study from the United Kingdom in 2007, rebleeding is associated with a higher mortality rate, potentially induces more extended hospital stay and need for reintervention[5]. Thus, preventing rebleeding is a critical factor from the patients' and a healthcare economic view. The management of non-variceal UGIB (NVUGIB) is well established in guidelines based on a high level of evidence. In the post-endoscopy care of NVUGIB, a strong recommendation is to use high-dose proton pump inhibitors and eradicate *Helicobacter pylori* (*H. pylori*) if presence is established[7]. On the other hand, if rebleeding happens,

Grade C (Good): 0
 Grade D (Fair): 0
 Grade E (Poor): 0

Received: June 16, 2021

Peer-review started: June 16, 2021

First decision: July 14, 2021

Revised: July 25, 2021

Accepted: September 16, 2021

Article in press: September 16, 2021

Published online: October 28, 2021

P-Reviewer: Liu XM,
 Papadopoulos VP, Xiong A, Ziogas
 IA

S-Editor: Ma YJ

L-Editor: A

P-Editor: Ma YJ



the patient should receive a repeat upper gastrointestinal endoscopy[7]. In the case of failure of this second attempt with endoscopic hemostasis, either transcatheter angiographic embolization (TAE) or rescue surgery are indicated, as they provide the same level of efficacy[8,9].

In contrast, there are only a few studies about the potential role of prophylactic transcatheter arterial embolization (PTAE) in the management of NVUGIB. A recent randomized controlled trial suggested that PTAE may reduce the incidence of recurrent bleeding (10.2% *vs* 11.4%, $P = 0.745$), but they could not show a clear benefit in adding angiographic embolization to endoscopic hemostasis in NVUGIB patients [10]. Investigating a subset of patients with ulcers 15mm or more in size, PTAE significantly reduced the risk of rebleeding (23.1% *vs* 4.5%, $P = 0.027$)[10]. A similar improvement in the rebleeding rate after PTAE was observed in some cohort studies [11-13].

Our study aimed to assess the role of PTAE among NVUGIB patients. We hypothesized that PTAE could reduce the risk of rebleeding and even the mortality rate among NVUGIB patients and improve other outcomes.

MATERIALS AND METHODS

We are reporting our systematic review and meta-analysis in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Statement [14] (Supplementary Table 1) and also in line with the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines[15] because we included both RCTs and observational cohort studies. Methods of the analysis and inclusion criteria were established in advance, and the protocol was documented on the International Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42021223726).

Systematic search

Three databases, MEDLINE (via PubMed), EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), were searched from inception through October 19th, 2020. We applied the following search key: (embolization OR embolisation) AND (peptic OR ulcer OR "gastrointestinal bleeding" OR nonvariceal OR non-variceal OR "gastrointestinal hemorrhage" OR "gastrointestinal haemorrhage"). We did not use any restrictions or filters during the search. We provide the complete search strategy in Supplementary Appendix 1.

Selection and eligibility

After the automatic and manual removal of duplicates with a reference manager software (EndNote X9, Clarivate Analytics, Philadelphia, PA, United States), screening and selection for the title, abstract, and full text were undertaken independently by two review authors. Cohen's kappa coefficient (κ) was calculated after each step to measure inter-reviewer reliability[16]. Disagreements were resolved through discussion with a third author. The references of the selected studies were examined to identify any additional relevant studies.

To identify eligible studies, we used the population-intervention-control-outcome (PICO) framework. Our investigated population (P) consisted of adult patients (age > 18 years) with endoscopy, digital subtraction angiography, or computed tomography angiography proved NVUGIB source, who either underwent successful endoscopic hemostasis or during angiography, there was no detectable contrast extravasation described. Studies compared the outcomes of patients who received PTAE (I) to patients who did not receive PTAE (C). The primary outcomes (O) were rebleeding and 30-d mortality rate, and the secondary outcomes were in-hospital or overall mortality rate, reintervention, need for salvage surgery, need of transfusion, length of hospital (LOH), and intensive care unit (ICU) stay. We pooled studies with different measurement time points regarding rebleeding (such as in-hospital, 28- and 30-d). If articles did not provide a precise measurement time point for mortality, we referred to that as "overall mortality". We defined reintervention as any repeated invasive treatment of rebleeding such as embolization, endoscopy, or surgery. Randomized controlled trials, prospective and retrospective observational cohort studies were eligible. Case reports, case series with less than ten patients, and review articles that did not report original research were excluded. In the case of publications using data with overlapping study populations, we used the one with the bigger sample size.

Data collection

Two independent review authors extracted data from eligible studies into a predesigned data collection form. The following data were collected from each study: first author, year of publication, study design, study period, study site (country), demographic features of the study population, the number of participants with PTAE, the number of patients without PTAE, bleeding etiology, type of embolic agents, data on outcomes (rebleeding, surgery, mortality, reintervention, LOH stay, ICU stay, and blood transfusion) in the intervention and control groups. In the case of the RCTs, intention-to-treat and per-protocol data were collected separately.

Data synthesis and statistical analysis

A biomedical statistician performed the statistical analysis of the study. Calculations were made by Stata 16 data analysis and statistical software (Stata Corp LLC, College Station, TX, United States). In the case of dichotomous categorical outcomes (mortality, rebleeding rate, *etc.*), we determined odds ratios (ORs) with 95% confidence intervals (95% CIs) from two-by-two tables (intervention *vs* control, outcome present and absent). For continuous variables, weighted mean difference (WMD) with 95% CIs were calculated. A *P* value less than 0.05 was considered a statistically significant difference. The random-effects model, according to the method of DerSimonian-Laird [17], was used to calculate the pooled estimates. We used forest plots to present the results of the meta-analyses.

*I*² and χ^2 tests were performed to assess heterogeneity. *I*² values were described as “minimal” (0%–40%), “moderate” (30%–60%), “substantial” (50%–90%), and “considerable” (75%–100%) heterogeneity, with a *P* value < 0.1 considered significant, as suggested by the Cochrane Handbook [18]. For the outcome of rebleeding, publication bias was assessed by visual inspection of a funnel plot and Egger's test. As for the other outcomes, we were unable to determine the presence of publication bias because of the low number of studies included in each analysis.

Sensitivity analysis was carried out by removing each trial analysis in turn in the case of rebleeding, reintervention, surgery, and need of transfusion outcome (the leave-one-out-method).

We performed a subgroup analysis for rebleeding and compared randomized controlled studies (RCTs) with non-randomized studies. For RCTs, we analyzed the intention-to-treat and per-protocol analysis results separately. Trial Sequential Analysis (TSA 0.9.5.10.) was performed for the RCTs regarding rebleeding to control random errors and estimate the optimal information size.

Risk of bias assessment and certainty of the evidence

Two independent review authors carried out the risk of bias assessment. Discrepancies were resolved by third-party arbitration. We followed the recommendations of the Cochrane Prognosis Methods group, and we used the revised Risk of Bias (RoB) 2 tool for randomized and the Risk of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool for non-randomized studies [19,20]. We used the Risk-of-bias VISualization (robvis) web-based tool [21].

Two independent review authors assessed the overall quality of evidence following the recommendation of the “Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)” workgroup [22]. A third author resolved disagreements. Summary of Findings table and the additional tables were prepared with the GRADE profiler (GRADEpro) tool [GRADEpro Guideline Development Tool (Software)]. McMaster University, 2020 (developed by Evidence Prime, Inc.).

RESULTS**Search and selection**

We identified 10591 records in three databases for evaluation. After removing duplicates and careful selection by title and abstract, 46 articles were eligible for full-text assessment. Altogether, 14 papers were retrieved for qualitative and 12 for quantitative synthesis. Two studies [23,24] were excluded from the quantitative synthesis due to major differences in intervention or outcome compared to other included articles. In the study of Ying *et al* [23], the intervention group got not only PTAE but also superior mesenteric arterial hypophysin infusion, which was too much alteration from our PICO and inclusion criteria. In the publication of Yonemoto *et al* [24], different outcomes (statistical analysis for laboratory data, number of endoscopic

treatments) were presented than we were assessing in our meta-analysis. The selection process is detailed in [Figure 1](#).

Characteristics of the studies included

The 14 included studies are summarized in [Table 1](#). We included in the quantitative synthesis three randomized controlled trials[10,25,26], two prospective[11,12], and seven retrospective cohort studies[13,27-32]. The source of bleeding was peptic ulcer lesions in eight studies[10-13,25,29,30,32], while in four studies[26-28,31], NVUGIB lesion was used as a generic term for various bleeding sources (*e.g.*, angiodysplasia, solid tumors, peptic ulcers). Each study had a relatively small sample size, with similar characteristics between intervention groups. The eligibility criteria of the studies included are presented in [Supplementary Table 2](#). Most of the studies did not report any adverse events during or after PTAE. Information about the reported endoscopic treatments, technical success rate of PTAE, adverse events, and standard of care are summarized in [Supplementary Table 3](#).

Prophylactic transcatheter arterial embolization is associated with lower odds of rebleeding

In our meta-analysis, we included a total of twelve studies with 1329 patients evaluating the clinical effect of PTAE on various outcomes. In the intervention group, 486 patients received PTAE in addition to standard of care. There was a total of 843 patients in the control group.

PTAE is connected with significantly lower chance for rebleeding compared to the control group (OR = 0.48, 95%CI: 0.29-0.78, $P = 0.003$; in a mildly heterogeneous dataset, $I^2 = 33.0\%$, $P = 0.126$) ([Figure 2](#)).

For this comparison, publication bias assessment by visual inspection of a funnel-plot and Egger's test was carried out, suggesting a likelihood for publication bias. ([Supplementary Figure 1](#)). Leave-one-out analysis showed no significant change in the overall odds for rebleeding ([Supplementary Figure 2](#)).

According to the RCT subgroup analysis with intention-to-treat data, there was no significant difference between the PTAE and control group in the rate of rebleeding (OR = 0.58, 95%CI: 0.27-1.25, $P = 0.165$; in a mildly heterogeneous dataset, $I^2 = 12.6\%$, $P = 0.319$) ([Figure 2](#)). However, with available per-protocol analysis results, the odds of rebleeding were significantly lower in the PTAE group, compared to the control group even according to the RCT subgroup analysis (OR = 0.42, 95%CI: 0.19-0.93, $P = 0.033$; [$I^2 = 0.0\%$, $P = 0.712$]) ([Supplementary Figure 3](#)). The performed TSA showed that the required information size was reached neither in the intention-to-treat nor in the per-protocol calculation ([Supplementary Figure 4A and 4B](#)).

Prophylactic transcatheter arterial embolization is not associated with mortality in non-variceal upper gastrointestinal bleeding

There was no significant difference neither in 30-day mortality [OR = 0.82, 95%CI: 0.39-1.72, $P = 0.594$; ($I^2 = 19.6\%$, $P = 0.290$)], nor in in-hospital mortality rates [OR = 0.46, 95%CI: 0.19-1.14, $P = 0.092$; ($I^2 = 0.0\%$, $P = 0.713$)], respectively] between the PTAE and control group ([Figure 3A](#)).

Prophylactic transcatheter arterial embolization seems to improve secondary outcomes in non-variceal upper gastrointestinal bleeding

Patients who underwent PTAE treatment were less likely to need any kind of reintervention caused by rebleeding, compared to those without PTAE (OR = 0.48, 95%CI: 0.31-0.76, $P = 0.002$; in a homogenous dataset, $I^2 = 0.0\%$, $P = 0.636$) ([Figure 3B](#)). We found that PTAE group has significantly lower odds of rescue surgery in contrast with the control group [OR = 0.35, 95%CI: 0.14-0.92, $P = 0.033$; ($I^2 = 44.1\%$, $P = 0.128$)] ([Supplementary Figure 5](#)). Leave-one-out analysis showed no major change in the overall odds of reintervention or rescue surgery ([Supplementary Figure 6 and 7](#)).

The length of hospital stay was reported in four studies[10-12,25]. Our meta-analysis established no statistically significant difference between the intervention and the control group in the length of hospital stay [WMD = -3.77 days, 95%CI: (-8.00)-0.45, $P = 0.08$; considerable heterogeneous dataset, $I^2 = 90.7\%$, $P < 0.001$] ([Figure 3C](#)). In parallel, three publications[10-12] reported the length of ICU stay, however the difference between the PTAE and control group was non-significant [WMD = -1.33 days, 95%CI: (-2.84)-0.18, $P = 0.084$; $I^2 = 84.8\%$, $P = 0.001$] ([Supplementary Figure 8](#)).

Table 1 Basic characteristics of included studies in the systematic review and meta-analysis

Ref.	Country	Study design	Study period	Number of patients/ intervention group	Female %	Age, ¹ (yr)	Bleeding etiology	Outcome(s)	Embolic agents
Arrayeah <i>et al</i> [27]	United States, Israel	Retrospective cohort	1997–2009	73/56	40	61.1	NVUGIB	Rebleeding, 30-d mortality, reintervention, surgery	Microcoils, gelatin sponge, polyvinyl alcohol particles
Dixon <i>et al</i> [28]	United Kingdom	Retrospective cohort	05.2008–11.2010	27/20	18.5	66	NVUGIB of duodenal origin	Rebleeding, 30-d mortality, reintervention	Microcoils alone or combined with gelatin/gelfoam sponge, polyvinyl alcohol particles
Kaminskis <i>et al</i> [11]	Latvia	Prospective cohort	2014–2018	399/58	44.4	67	High-risk peptic ulcer	Rebleeding, in-hospital mortality, surgery, hospital stay, ICU stay, transfused blood units	ND
Kaminskis <i>et al</i> [12]	Latvia	Prospective cohort	2010–2013	75/25	66.6	64	High-risk peptic ulcer	Rebleeding, in-hospital mortality, surgery, hospital stay, ICU stay, transfused blood units	Coil or sandwich technique
Lau <i>et al</i> [10]	China	Randomized controlled trial	2010–2014	241/118	24.9	66	High-risk peptic ulcer	Rebleeding, 30-d mortality, reintervention, surgery, hospital stay, ICU stay, transfused blood units	Sandwich technique: Coils and gel foam particles
Laursen <i>et al</i> [25]	Denmark	Randomized controlled trial	11.2009–05.2012	105/49	44	73	High-risk peptic ulcer	Rebleeding, in-hospital and 30-d mortality, hospital stay, readmission	Coils
Lebedev <i>et al</i> [29]	Russia	Retrospective cohort	1991–2016	90/30	ND	ND	Peptic ulcer	Rebleeding, mortality	Microcoils, polyvinyl alcohol
Mille <i>et al</i> [30]	Germany	Retrospective cohort	2008–2012	102/55	31.4	70.7	Duodenal ulcer	Rebleeding, 30-d mortality, surgery, transfused blood units	Coils, cyanoacrylate glue or both
Sildiroglu <i>et al</i> [31]	United States	Retrospective cohort	10.2001–11.2011	43/18	ND	60.1	NVUGIB	Rebleeding, mortality	Coils, gelfoam, polyvinyl alcohol
Tong <i>et al</i> [13]	China	Retrospective cohort	2014–2016	74/16	23	57.2	High-risk peptic ulcer	Rebleeding	ND
Wu <i>et al</i> [32]	Australia	Retrospective cohort	01.2008–12.2012	34/8	ND	70.1	Peptic ulcer	Rebleeding	ND
Ying <i>et al</i> [26]	China	Randomized controlled trial	05.2012–06.2013	66/33	25	51.5	Upper GIB	Rebleeding	Gelatin sponge particles
Ying <i>et al</i> [23]	China	Randomized controlled trial	06.2010–06.2014	78/39	46.2	46.5	Upper GIB	Short term haemostasis, long term haemostasis, hospital stay, transfusion	Coils, gelatin sponge
Yonemoto <i>et al</i> [24]	Japan	Retrospective cohort	04.2005–12.2017	141/11	22.7	62.8	Duodenal ulcer	Laboratory data at initial diagnosis, the amount of blood transfusion, 30-d mortality	ND

¹Age is given in mean or median. GIB: Gastrointestinal bleeding, ICU: Intensive care unit, ND: No data, NVUGIB: Non-variceal upper GIB.

Lastly, the PTAE group needed significantly more units of blood transfusion, than




Figure 1 Preferred reporting in systematic reviews and meta-analyses flowchart showing the selection process.

Risk of bias assessment and quality of evidence

Among the included studies, four[10-12,25] were of low overall risk of bias, two[29,30] were of high overall risk of bias, all the other studies were rated to carry moderate overall risk of bias. The summary of the risk of bias assessment is shown in [Supplementary Figure 11-18](#).

We included all outcomes in the "Summary of findings table" ([Supplementary Table 4](#)). The certainty of the evidence is very low for every outcome because our meta-analysis mainly contained observational studies. We calculated the quality of evidence among the RCT subgroup in rebleeding, and we found a moderate certainty of the evidence for PTAE, lowering the chance of rebleeding.

DISCUSSION

In this study, we assessed the effect of PTAE in addition to the successful endoscopic treatment of NVGIB or PTAE as the first treatment option in case of not actively bleeding patients with NVUGIB lesions. Based on our findings, PTAE is associated with lower odds of rebleeding, need for additional reintervention, and rescue surgery compared to standard of care. We found a roughly 50% lower rate of the outcomes mentioned above, which is a considerable proportion, especially considering the prevalence of NVUGIB.




Figure 2 Forest plot of studies divided into subgroups representing that the overall odds of rebleeding were significantly lower in the prophylactic transcatheter arterial embolization group. However, among the RCT studies, the difference was not statistically significant. RCT: Randomized controlled trial; OR: Odds ratio; 95%CI: Confidence interval.

A recent meta-analysis of Chang *et al*[33] attempted to evaluate the role of PTAE in the management of patients with high-risk peptic ulcer bleeding. They included only 2 RCTs and 3 observational studies in their meta-analysis while narrowing their search to patients with a high risk of rebleeding. We designed our systematic search for NVUGIB without restriction to high-risk peptic ulcer bleeding because of the various NVUGIB bleeding etiologies that could be treated with TAE[9].


Rebleeding in the randomized controlled trials

We found three eligible RCTs[10,25,26], which provide the core of our meta-analysis and the highest level of evidence. When we performed a subgroup analysis of the RCTs for the rebleeding outcome, we found no significant difference between PTAE and the control group. We think that the main reason why with intention-to-treat data, we could not demonstrate the clear beneficial effect of PTAE is that in Lau *et al*[10]'s study, 22 patients out of 118 (18.6%), and Laursen *et al*[25], 18 out of 49 (36.7%) did not receive embolization at all despite being in the embolization arm of the studies. When we used per-protocol data, also in the RCT subgroup, there was a significantly lower risk for rebleeding in the PTAE group. However, the TSA calculation showed that the required information size was not reached, and our results are inconclusive.


It is important to note that in Laursen *et al*[25]'s study, 9% of the potentially eligible patients were excluded because they were admitted to the hospital on weekends. These patients could not receive the allocated intervention due to the lack of staff in interventional radiology. This highlights that PTAE could be the most beneficial treatment option in centers with well-established interventional radiology units.

According to Lau *et al*[10], the chance of recurrent bleeding was significantly reduced in ulcers 15 mm in size or greater. Unfortunately, there was not enough data on the size of the culprit lesions in the other included studies to perform a meta-analysis. Nevertheless, risk stratification is essential before choosing between multiple possible treatment modalities in the case of NVUGIB. Several studies[10-13,25] used the Forrest classification, Rockall score, or the American Society of Anesthesiologists

A



B



C




Figure 3 Forest plot of studies. A: Representing no significant difference in mortality rates between the prophylactic transcatheter arterial embolization and the control group; B: Representing significantly lower odds of reintervention in the prophylactic transcatheter arterial embolization than the control group; C: representing no significant difference in length of hospital stay in days between the prophylactic transcatheter arterial embolization and the control group. OR: Odds ratio; 95%CI: Confidence interval; WMD: Weighted mean difference; SD: Standard deviation.

score to assess the baseline risk of rebleeding or mortality among the patients, and it was approximately the same between the PTAE and the control group.

Rebleeding in cohort studies

The publication of Mille *et al*[30] described that only high rebleeding risk patients got PTAE, and in the control group were only low-risk patients. We consider this a selection bias, causing confounding of the measured outcomes, which could explain why they did not manage to find any difference in the rebleeding, reintervention, or rescue surgery rate between the intervention and the control group. Applying the leave-one-out method in the case of the study of Mille *et al*[30], there was no major change in the overall odds for rebleeding, reintervention, and rescue surgery.

The study of Sildiroglu *et al*[31] was the only one where the PTAE group had a worse rebleeding rate than the control group. There was no data on the baseline characteristics of the two treatment groups, so we cannot explain this contradicting result.

We included in our analyses four studies[26-28,31], with a definition of NVUGIB including various sources such as peptic ulcers, tumors, Dieulafoy lesion, Mallory-Weiss tear. Arrayeh *et al*[27] carried out a retrospective analysis that compared three therapeutic options: angiography without embolization, PTAE, and TAE with an abnormal angiogram. They published the interesting observation that patients with duodenal bleeding due to a mass (various types of malignant) lesion had a greater primary hemostasis rate 30 d after angiography compared with patients with nonmass (different types of benign) sources of duodenal bleeding (100% vs 54%; $P = 0.008$). This difference was not detectable between mass and nonmass lesions in the case of gastric bleeding. We did not find data in other studies about the investigated outcomes separated by the type of the bleeding lesion.

The rebleeding rate could also depend on whether NVUGIB has a gastric or duodenal source. According to Arrayeh *et al*[27], PTAE may be advantageous in patients with a duodenal source of bleeding but not in patients with gastric hemorrhage. We did not identify enough evidence to support this inference because none of the other included studies reported gastric and duodenal bleeding separately.

Evidence about secondary outcomes

Our results indicated that PTAE does not improve the mortality rates of NVUGIB significantly. We could not draw a clear conclusion about this outcome because of the different time-frames for mortality assessment used between the different studies: 30-d mortality was used in five studies[10,25,27,28,30], in-hospital mortality in three[11,12,25] and two studies[29,31] did not report any time-frame for mortality. Mortality is strongly associated with pre-endoscopy and complete Rockall score, according to Hearnshaw *et al*[5] We can only speculate that numerous major confounding factors affect the mortality of NVUGIB patients, and only one of them is the chosen treatment modality.

We had predicted a shorter hospital stay and ICU stay in the PTAE group, but our findings could not prove a significant difference between the two groups. Interestingly, if we analyzed only the data coming from RCTs, there was an apparent reduction in the length of hospital and ICU stay in the PTAE group compared with the control group. This result highlights the possible bias of the observational cohort studies.

The PTAE group needed slightly more red blood cell transfusion than the control group, although the heterogeneity between the studies suggests a careful interpretation of this finding. Since we assume a major confounding factor in the publication of Mille *et al*[30], the difference was no longer statistically significant between the PTAE and the control group after applying the leave-one-out method.

Methods reducing rebleeding risk in non-variceal upper gastrointestinal bleeding

There are a few therapies, which are already proved to reduce rebleeding from NVUGIB. Proton pump inhibitors (PPI) significantly decrease the recurrence of bleeding compared to control (placebo or histamine type 2 receptor antagonists); pooled rates were 10.6% with PPI *vs* 17.3% with control treatment (OR = 0.49; 95%CI: 0.37-0.65) in a Cochrane review comprising 24 RCTs[34]. Our recent meta-analysis showed that PPIs given either orally or intravenously are equally efficacious in preventing rebleeding[35].

After peptic ulcer bleeding, investigation for the presence of *H. pylori* should be mandatory. Our network meta-analysis[36] demonstrated that none of the individual tests or the strategy of combined tests is superior in detecting *H. pylori*. Gisbert *et al*[37] reported that rebleeding did not occur in patients with complicated ulcers after *H. pylori* eradication; moreover, maintenance of anti-ulcer therapy is unnecessary if eradication was achieved.

Endoscopic Doppler probe guided hemostasis significantly reduced the 30-d rates of rebleeding compared with standard visually guided hemostasis in an RCT (11.1% *vs* 26.3%), and the use of the endoscopic Doppler probe was suggested for risk stratification in the management of NVUGIB[38].

Another promising endoscopic technique to reduce the rebleeding rate of peptic ulcers is over-the-scope clipping (OTSC), which is superior to standard therapy with through-the-scope clips in preventing further bleeding according to the prospective RCT of Schmidt *et al*[39].

A recent meta-analysis[40] showed that the routine second-look endoscopy was not superior to a single endoscopy with complete endoscopic hemostasis in reducing the risk of recurrent bleeding, mortality, or need for surgery in patients with acute UGIB due to peptic ulcer disease. In contrast, according to our results, PTAE added to the standard of care could decrease the probability of rebleeding. Moreover, PTAE might reduce the need for surgery and any reintervention.

Strengths and limitations

Our work is assessing the potential effects of PTAE compared to the standard of care in the treatment of NVUGIB. We used a rigorous methodology and followed a transparent protocol, combined with a comprehensive statistical analysis as possible. We collected a total of 486 patients who received PTAE, which is an infrequent therapeutic choice so far.

The main limitation of our meta-analysis is that we collected our data mostly from observational cohort studies, and we found only three RCTs comparing PTAE to the standard of care. Thus, the quality of evidence for every outcome in our meta-analysis is very low based on the GRADE framework. When we assessed the quality of evidence regarding rebleeding in the RCT subgroup, we found moderate evidence for the risk reduction with PTAE. The diversity of the NVUGIB population in some studies could also limit our results and explain the statistical heterogeneity in some cases. Significant differences are present in the embolic agents utilized for PTAE

among publications. There was very restricted data on the endoscopic treatment before PTAE, which could also influence the outcomes. The included studies contain only limited information on secondary outcomes, so our conclusions about these are less certain.

Implications for practice

In selected cases, where the previous risk stratification suggests high rebleeding risk or the anatomical situation makes the secure and permanent endoscopic hemostasis impossible, we can consider the routine use of PTAE. Considering the demographic trends of NVUGIB, we predict that elderly, high-risk patients with co-morbidities could benefit the most from PTAE as a therapeutic approach.

Implications for research

Further RCTs are warranted to achieve a higher level of evidence about the potentially beneficial effects of PTAE. Developing an accurate risk stratification system would be crucial to select the ideal candidates for PTAE. Clinical trials investigating the use of existing risk scores or creating a new risk stratification tool of NVUGIB could help clinicians choose between the emerging number of treatment options.

CONCLUSION

PTAE is accompanied by lower odds of rebleeding, need for surgery, and reinterventions in NVUGIB. However, our meta-analysis could not justify a beneficial effect of PTAE on mortality rates compared with the standard of care in NVUGIB.

ARTICLE HIGHLIGHTS

Research background

The prevention of rebleeding is one of the main goals in managing non-variceal upper gastrointestinal bleeding (NVUGIB). Prophylactic transcatheter arterial embolization (PTAE) can be used in NVUGIB as second-line therapy.

Research motivation

The results of the individual studies about the beneficial effects of PTAE among NVUGIB patients were contradictory.

Research objectives

The authors aimed to carry out a comprehensive systematic review and meta-analysis. The authors compared the PTAE to no embolization as a second line, prophylactic treatment among NVUGIB patients.

Research methods

The authors conducted a systematic search in three databases (MEDLINE, EMBASE, CENTRAL). The eligible studies compared patients with NVUGIB receiving PTAE to those who did not get PTAE. The authors calculated odds ratios (ORs) with 95% confidence intervals (CI) for rebleeding, mortality, reintervention, need for surgery, and weighted mean differences (WMDs) of need for transfusion, length of hospital (LOH), and intensive care unit (ICU) stay.

Research results

PTAE was associated with significantly lower odds of rebleeding, reintervention and rescue surgery (OR = 0.48, 95%CI: 0.29–0.78; OR = 0.48, 95%CI: 0.31–0.76; OR = 0.35, 95%CI: 0.14–0.92; respectively). There was no significant difference in the mortality rates, LOH, and ICU stays between the PTAE and control groups. The quality of evidence for every outcome in our meta-analysis is very low based on the GRADE framework.

Research conclusions

The results suggest that PTAE is a reasonable therapeutic choice to prevent rebleeding or reintervention in NVUGIB, although it did not improve the mortality rates of NVUGIB.

Research perspectives

Further randomized controlled trials are needed about the use of PTAE. We also propose a clinical trial that could recommend a new risk stratification tool of NVUGIB, helping clinicians choose between treatment options.

REFERENCES

- 1 **Loperfido S**, Baldo V, Piovesana E, Bellina L, Rossi K, Groppo M, Caroli A, Dal Bò N, Monica F, Fabris L, Salvat HH, Bassi N, Okolicsanyi L. Changing trends in acute upper-GI bleeding: a population-based study. *Gastrointest Endosc* 2009; **70**: 212-224 [PMID: 19409558 DOI: 10.1016/j.gie.2008.10.051]
- 2 **Oakland K**. Changing epidemiology and etiology of upper and lower gastrointestinal bleeding. *Best Pract Res Clin Gastroenterol* 2019; **42-43**: 101610 [PMID: 31785737 DOI: 10.1016/j.bpg.2019.04.003]
- 3 **Wuerth BA**, Rockey DC. Changing Epidemiology of Upper Gastrointestinal Hemorrhage in the Last Decade: A Nationwide Analysis. *Dig Dis Sci* 2018; **63**: 1286-1293 [PMID: 29282637 DOI: 10.1007/s10620-017-4882-6]
- 4 **Jairath V**, Martel M, Logan RF, Barkun AN. Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? *Can J Gastroenterol* 2012; **26**: 537-543 [PMID: 22891179 DOI: 10.1155/2012/862905]
- 5 **Hearnshaw SA**, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. *Gut* 2011; **60**: 1327-1335 [PMID: 21490373 DOI: 10.1136/gut.2010.228437]
- 6 **van Leerdam ME**. Epidemiology of acute upper gastrointestinal bleeding. *Best Pract Res Clin Gastroenterol* 2008; **22**: 209-224 [PMID: 18346679 DOI: 10.1016/j.bpg.2007.10.011]
- 7 **Gralnek IM**, Stanley AJ, Morris AJ, Camus M, Lau J, Lanas A, Laursen SB, Radaelli F, Papanikolaou IS, Cúrdia Gonçalves T, Dinis-Ribeiro M, Awadie H, Braun G, de Groot N, Udd M, Sanchez-Yague A, Neeman Z, van Hooft JE. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. *Endoscopy* 2021; **53**: 300-332 [PMID: 33567467 DOI: 10.1055/a-1369-5274]
- 8 **Nykänen T**, Peltola E, Kylänpää L, Udd M. Bleeding gastric and duodenal ulcers: case-control study comparing angioembolization and surgery. *Scand J Gastroenterol* 2017; **52**: 523-530 [PMID: 28270041 DOI: 10.1080/00365521.2017.1288756]
- 9 **Tarasconi A**, Baiocchi GL, Pattonieri V, Perrone G, Abongwa HK, Molfino S, Portolani N, Sartelli M, Di Saverio S, Heyer A, Ansaloni L, Coccolini F, Catena F. Transcatheter arterial embolization versus surgery for refractory non-variceal upper gastrointestinal bleeding: a meta-analysis. *World J Emerg Surg* 2019; **14**: 3 [PMID: 30733822 DOI: 10.1186/s13017-019-0223-8]
- 10 **Lau JYW**, Pittayanon R, Wong KT, Pinjaroen N, Chiu PWY, Rerknimitr R, Holster IL, Kuipers EJ, Wu KC, Au KWL, Chan FKL, Sung JYJ. Prophylactic angiographic embolisation after endoscopic control of bleeding to high-risk peptic ulcers: a randomised controlled trial. *Gut* 2019; **68**: 796-803 [PMID: 29802172 DOI: 10.1136/gutjnl-2018-316074]
- 11 **Kaminskis A**, Ivanova P, Kratovska A, Ponomarjova S, Ptašņuka M, Demičevs J, Demičeva R, Boka V, Pupelis G. Endoscopic hemostasis followed by preventive transarterial embolization in high-risk patients with bleeding peptic ulcer: 5-year experience. *World J Emerg Surg* 2019; **14**: 45 [PMID: 31516544 DOI: 10.1186/s13017-019-0264-z]
- 12 **Kaminskis A**, Kratovska A, Ponomarjova S, Tolstova A, Mukans M, Stabiņa S, Gailums R, Bernšteins A, Ivanova P, Boka V, Pupelis G. Preventive transarterial embolization in upper nonvariceal gastrointestinal bleeding. *World J Emerg Surg* 2017; **12**: 3 [PMID: 28101125 DOI: 10.1186/s13017-016-0114-1]
- 13 **Tong H**, Lan T, Tang CW. Prophylactic angiographic embolisation after endoscopic treatment of bleeding for high-risk peptic ulcers: what are the more appropriate indications? *Gut* 2020; **69**: 1897-1898 [PMID: 31776229 DOI: 10.1136/gutjnl-2019-319818]
- 14 **Page MJ**, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; **372**: n71 [PMID: 33782057 DOI: 10.1136/bmj.n71]
- 15 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]
- 16 **McHugh ML**. Interrater reliability: the kappa statistic. *Biochem Med (Zagreb)* 2012; **22**: 276-282 [PMID: 23092060]
- 17 **DerSimonian R**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]
- 18 **Higgins JPT**, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane*

- Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from: <https://training.cochrane.org/handbook>
- 19 **Sterne JA**, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016; **355**: i4919 [PMID: 27733354 DOI: 10.1136/bmj.i4919]
 - 20 **Sterne JAC**, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; **366**: 14898 [PMID: 31462531 DOI: 10.1136/bmj.14898]
 - 21 **McGuinness LA**, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Res Synth Methods* 2021; **12**: 55-61 [PMID: 32336025 DOI: 10.1002/jrsm.1411]
 - 22 **Iorio A**, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, Wolff R, Kujpers T, Perel P, Vandvik PO, Glasziou P, Schunemann H, Guyatt G. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ* 2015; **350**: h870 [PMID: 25775931 DOI: 10.1136/bmj.h870]
 - 23 **Ying Y**, Luo JF, He X, Zeng FL, Xie YL. Clinical effects of preventive interventional therapy in gastrointestinal bleeding patients with negative digital subtraction angiography findings. *Shijie Huaren Xiaohua Zazhi* 2014; **22**: 5556-5560 [DOI: 10.11569/wejd.v22.i35.5556]
 - 24 **Yonemoto Y**, Fukami Y, Hara H, Mochida T, Machida T, Sugiyama Y, Watanabe A, Kaneshiro M, Ikemiyagi H, Yoshino K, Sakita S. The statistical comparison of endoscopic procedure and transarterial embolization for hemorrhage caused by duodenal ulcer. *United European Gastroenterol J* 2018; **6**: A496-A497 [DOI: 10.1177/2050640618792819]
 - 25 **Laursen SB**, Hansen JM, Andersen PE, Schaffalitzky de Muckadell OB. Supplementary arterial embolization an option in high-risk ulcer bleeding--a randomized study. *Scand J Gastroenterol* 2014; **49**: 75-83 [PMID: 24256098 DOI: 10.3109/00365521.2013.854829]
 - 26 **Ying Y**, Luo JF, Zhang WH, Wang XN, He X. Effects of vasopressin infusion aided prophylactic gastroduodenal artery embolization in DSA-negative gastrointestinal bleeding patients. *Shijie Huaren Xiaohua Zazhi* 2013; **21**: 4180-4184 [DOI: 10.11569/wejd.v21.i36.4180]
 - 27 **Arrayeh E**, Fidelman N, Gordon RL, LaBerge JM, Kerlan RK Jr, Klimov A, Bloom AI. Transcatheter arterial embolization for upper gastrointestinal nonvariceal hemorrhage: is empiric embolization warranted? *Cardiovasc Intervent Radiol* 2012; **35**: 1346-1354 [PMID: 22302348 DOI: 10.1007/s00270-012-0351-y]
 - 28 **Dixon S**, Chan V, Shrivastava V, Anthony S, Uberoi R, Bratby M. Is there a role for empiric gastroduodenal artery embolization in the management of patients with active upper GI hemorrhage? *Cardiovasc Intervent Radiol* 2013; **36**: 970-977 [PMID: 23152041 DOI: 10.1007/s00270-012-0511-0]
 - 29 **Lebedev NV**, Belozherov GE, Klimov AE, Sokolova PY, Spasskiy AA, Barkhudarov AA. [Transcatheter embolization in prevention of recurrent bleeding from stomach ulcers]. *Khirurgiia (Mosk)* 2017; **31**: 31-35 [PMID: 28514380 DOI: 10.17116/hirurgia2017531-35]
 - 30 **Mille M**, Huber J, Wlasak R, Engelhardt T, Hillner Y, Kriechling H, Aschenbach R, Ende K, Scharf JG, Puls R, Stier A. Prophylactic Transcatheter Arterial Embolization After Successful Endoscopic Hemostasis in the Management of Bleeding Duodenal Ulcer. *J Clin Gastroenterol* 2015; **49**: 738-745 [PMID: 25319738 DOI: 10.1097/MCG.0000000000000259]
 - 31 **Sildiroglu O**, Muasher J, Arslan B, Sabri SS, Saad WE, Angle JF, Matsumoto AH, Turba UC. Outcomes of patients with acute upper gastrointestinal nonvariceal hemorrhage referred to interventional radiology for potential embolotherapy. *J Clin Gastroenterol* 2014; **48**: 687-692 [PMID: 25014238 DOI: 10.1097/MCG.0000000000000181]
 - 32 **Wu P**, Szczesniak MM, Craig PI, Choo L. A novel predictor of rebleeding in high risk peptic ulcer disease selects patients who would benefit most from prophylactic arterial embolisation. *Gastroenterology* 2014; **146**: S-183 [DOI: 10.1016/S0016-5085(14)60650-8]
 - 33 **Chang JHE**, Lye TJY, Zhu HZ, Syn NL, Tang SS, Gogna A, Chan WH, Ong HS, Tan JTH, Lim CH. Systematic Review and Meta-Analysis of Prophylactic Transarterial Embolization for High-Risk Bleeding Peptic Ulcer Disease. *J Vasc Interv Radiol* 2021; **32**: 576-584.e5 [PMID: 33526343 DOI: 10.1016/j.jvir.2020.12.005]
 - 34 **Leontiadis GI**, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. *Cochrane Database Syst Rev* 2006; CD002094 [PMID: 16437441 DOI: 10.1002/14651858.CD002094.pub3]
 - 35 **Csik E**, Szabó H, Hanák L, Szakács Z, Kiss S, Vörhendi N, Pécsi D, Hegyi E, Hegyi P, Eröss B. Oral Proton Pump Inhibitors May Be as Effective as Intravenous in Peptic Ulcer Bleeding: A Systematic Review and Meta-analysis. *Clin Transl Gastroenterol* 2021; **12**: e00341 [PMID: 33988530 DOI: 10.14309/ctg.0000000000000341]
 - 36 **Vörhendi N**, Soós A, Anne Engh M, Tinusz B, Szakács Z, Pécsi D, Mikó A, Sarlós P, Hegyi P, Eröss B. Accuracy of the *Helicobacter pylori* diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis. *Therap Adv Gastroenterol* 2020; **13**: 1756284820965324 [PMID: 33403002 DOI: 10.1177/1756284820965324]

- 37 **Gisbert JP**, Calvet X, Cosme A, Almela P, Feu F, Bory F, Santolaria S, Aznárez R, Castro M, Fernández N, García-Grávalos R, Benages A, Cañete N, Montoro M, Borda F, Pérez-Aisa A, Piqué JM; H. pylori Study Group of the Asociación Española de Gastroenterología (Spanish Gastroenterology Association). Long-term follow-up of 1,000 patients cured of *Helicobacter pylori* infection following an episode of peptic ulcer bleeding. *Am J Gastroenterol* 2012; **107**: 1197-1204 [PMID: 22613904 DOI: 10.1038/ajg.2012.132]
- 38 **Jensen DM**, Kovacs TOG, Ohning GV, Ghassemi K, Machicado GA, Dulai GS, Sedarat A, Jutabha R, Gornbein J. Doppler Endoscopic Probe Monitoring of Blood Flow Improves Risk Stratification and Outcomes of Patients With Severe Nonvariceal Upper Gastrointestinal Hemorrhage. *Gastroenterology* 2017; **152**: 1310-1318.e1 [PMID: 28167214 DOI: 10.1053/j.gastro.2017.01.042]
- 39 **Schmidt A**, Gölder S, Goetz M, Meining A, Lau J, von Delius S, Escher M, Hoffmann A, Wiest R, Messmann H, Kratt T, Walter B, Bettinger D, Caca K. Over-the-Scope Clips Are More Effective Than Standard Endoscopic Therapy for Patients With Recurrent Bleeding of Peptic Ulcers. *Gastroenterology* 2018; **155**: 674-686.e6 [PMID: 29803838 DOI: 10.1053/j.gastro.2018.05.037]
- 40 **Kamal F**, Khan MA, Lee-Smith W, Sharma S, Imam Z, Henry C, Jowhar D, Khan Z, Petryna E, Iqbal U, Tombazzi C, Ismail MK, Howden CW. Role of routine second-look endoscopy in patients with acute peptic ulcer bleeding: meta-analysis of randomized controlled trials. *Gastrointest Endosc* 2021; **93**: 1228-1237.e5 [PMID: 33417896 DOI: 10.1016/j.gie.2020.12.039]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

